ZFP36

Across TCGA pan-cancer cohorts, ZFP36 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZFP36 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZFP36 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFP36 expression acts as an unfavorable survival marker.

OV and PAAD are the cancer types where ZFP36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.168	0.541	.005	18	view →
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ZFP36–OV (DFS)

Open the OV breakdown →